spiro[7-azabicyclo[3.3.1]nonane-3.2'-[1,3]dioxolane] | 199874-18-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: spiro[7-azabicyclo[3.3.1]nonane-3.2'-[1,3]dioxolane]
• 英文别名: Spiro[7-azabicyclo[3.3.1]nonane-3,2'-[1,3]dioxolane]；spiro[1,3-dioxolane-2,7'-3-azabicyclo[3.3.1]nonane]
• CAS: 199874-18-5
• 化学式: C₁₀H₁₇NO₂
• 分子量: 183.25
• InChiKey: LZHZPGJJDYMDEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  spiro[7-azabicyclo[3.3.1]nonane-3.2'-[1,3]dioxolane] 在 4-二甲氨基吡啶 、 1,1'-双(二苯基膦)二茂铁 、 potassium acetate 、 palladium diacetate 、 potassium carbonate 、 对甲苯磺酸 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 21.15h， 生成
  参考文献：
  名称：

  Structure–Activity Studies of 7-Heteroaryl-3-azabicyclo[3.3.1]non-6-enes: A Novel Class of Highly Potent Nicotinic Receptor Ligands

  摘要：

  The potential for nicotinic ligands with affinity for the alpha 4 beta 2 or alpha 7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while preclinical activity in relevant in vivo models has been demonstrated for many more. For several therapeutic programs, we sought nicotinic ligands with various combinations of affinity and function across both subtypes, with an emphasis on dual alpha 4 beta 2-alpha 7 ligands, to explore, the possibility of synergistic effects. We report here the structure-activity relationships (SAR) for a novel series of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes and characterize many of the analogues for activity at multiple nicotinic subtypes.

  DOI：

  10.1021/jm3011299
• 作为产物：
  描述：

  1,4-dioxa-spiro[4.5]decane-7,9-dicarboxylic acid dimethyl ester 在 甲酸铵 、 palladium(II) hydroxide 、 二异丁基氢化铝 作用下， 以 乙醇 、 正己烷 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 spiro[7-azabicyclo[3.3.1]nonane-3.2'-[1,3]dioxolane]
  参考文献：
  名称：

  Structure–Activity Studies of 7-Heteroaryl-3-azabicyclo[3.3.1]non-6-enes: A Novel Class of Highly Potent Nicotinic Receptor Ligands

  摘要：

  The potential for nicotinic ligands with affinity for the alpha 4 beta 2 or alpha 7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while preclinical activity in relevant in vivo models has been demonstrated for many more. For several therapeutic programs, we sought nicotinic ligands with various combinations of affinity and function across both subtypes, with an emphasis on dual alpha 4 beta 2-alpha 7 ligands, to explore, the possibility of synergistic effects. We report here the structure-activity relationships (SAR) for a novel series of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes and characterize many of the analogues for activity at multiple nicotinic subtypes.

  DOI：

  10.1021/jm3011299

文献信息

• Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders
  申请人：Breining Scott R.

  公开号：US20080242693A1

  公开（公告）日：2008-10-02

  Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

  患有或易感染神经系统紊乱（例如帕金森氏症、多动症、注意力缺陷障碍、精神分裂症等）的患者，其特征为神经递质释放（例如多巴胺释放）的异常改变，可通过给予本文所述的1或2式化合物治疗。1和2式化合物也可用于治疗疼痛、药物成瘾、尼古丁成瘾和/或肥胖症。这些化合物可以存在为单一立体异构体、混合物、对映异构体等形式。
• Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
  申请人：Martin Fionna Mitchell

  公开号：US20080261999A1

  公开（公告）日：2008-10-23

  Compounds of the formula I or a pharmaceutically acceptable salt thereof: processes for their preparation, pharmaceutical compositions which contain them and their uses in therapy.

  公式I的化合物或其药学上可接受的盐：制备它们的过程，包含它们的制药组合物以及它们在治疗中的用途。
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：Breining Scott R.

  公开号：US20100152228A1

  公开（公告）日：2010-06-17

  Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

  对于易感或患有中枢神经系统疾病的患者，这些疾病的特点是神经递质释放的正常变化，例如多巴胺释放（例如帕金森病，托瑞特综合症，注意力缺陷障碍或精神分裂症），可以通过给予本文所述的1或2式化合物来治疗。1和2式化合物也可用于治疗疼痛，药物成瘾，尼古丁成瘾和/或肥胖症。这些化合物可以存在于单个立体异构体，混合物，对映异构体等形式。
• [EN] AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET METHODES DESTINEES AU SOULAGEMENT DE LA DOULEUR ET AU TRAITEMENT DE TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：TARGACEPT INC

  公开号：WO2005037832A3

  公开（公告）日：2005-06-16
• WO2006/96358
  申请人：——

  公开号：——

  公开（公告）日：——